Galmed Pharmaceuticals Ltd.
GLMD
$1.56
$0.00430.28%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 66.83% | 10.14% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 66.85% | -23.11% | |||
| Operating Income | -66.85% | 23.11% | |||
| Income Before Tax | -126.00% | 65.60% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -126.00% | 65.60% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -126.00% | 65.60% | |||
| EBIT | -66.85% | 23.11% | |||
| EBITDA | -67.96% | 24.37% | |||
| EPS Basic | -1.87% | 68.94% | |||
| Normalized Basic EPS | 19.60% | 51.49% | |||
| EPS Diluted | -1.87% | 68.94% | |||
| Normalized Diluted EPS | 19.60% | 51.49% | |||
| Average Basic Shares Outstanding | 121.85% | 10.75% | |||
| Average Diluted Shares Outstanding | 121.85% | 10.75% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||